Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical Products Administration (NMPA) for its HX009, a bifunctional macromolecule targeting PD-1 and CD47. The company plans to test the investigational cancer immunotherapy in combination with an antibody drug conjugate (ADC) for triple-negative breast cancer (TNBC) in a Phase II study.
Drug Profile
HX009 has completed two Phase I single-dose escalation studies in Australia and China. The drug received approval for study in recurrent/refractory lymphoma in the US in May 2023. The upcoming Phase II trial will evaluate its efficacy and safety in TNBC patients.-Fineline Info & Tech
